Novavax (NVAX) Reports Positive Phase 1 Data for COVID-19 Vaccine Candidate

Novavax (NVAX) PT Raised to $257 at B.Riley/FBR

August 5, 2020 6:57 AM EDT

B.Riley/FBR analyst Chad L. Mabry raised the price target on Novavax (NASDAQ: NVAX) to $257.00 (from $184.00) while maintaining a Buy rating.

... More

UPDATE: JPMorgan Upgrades Novavax (NVAX) to Overweight

August 5, 2020 4:40 AM EDT

(Updated - August 5, 2020 4:59 AM EDT)

(updating comment)

JPMorgan analyst Eric Joseph upgraded Novavax (NASDAQ: NVAX) from Neutral to Overweight with a price target of $275.00 (from $105.00).

The analyst comments "We are Overweight rated on NVAX shares. Post recent phase 1 results with... More

After-Hours Stock Movers 08/04: (ARPO) (NVAX) (LPSN) Higher; (VAPO) (NEWR) (BYND) Lower (more...)

August 4, 2020 6:07 PM EDT

Today's After-Hours Stock Movers

Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO) 62% HIGHER; Aerpio Pharmaceuticals and The U.S. Government operating through the Medical Technology Enterprise Consortium (MTEC) announced today that an agreement has been reached to evaluate razuprotafib in a new randomized, investigational trial for the prevention and treatment of Acute Respiratory Distress Syndrome (ARDS) in adult patients with moderate to severe COVID-19 as part of MTEC-20-09-COVID-19 Treatment Military Infectious Disease Research Program (MIDRP) Development of Treatments for COVID-19. MTEC will provide up to $5.1 million in... More

Novavax (NVAX) Erases Post-Market Decline, Now Up 13%

August 4, 2020 5:46 PM EDT

Novavax (NASDAQ: NVAX) Erases Post-Market Decline, Now Up 13%

... More

Novavax (NVAX) says phase 1 data for COVID-19 vaccine candidate show it was generally well-tolerated and elicited robust antibody responses

August 4, 2020 4:06 PM EDT

Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of its COVID19 vaccine with and without MatrixM adjuvant in healthy adults 18-59 years of age. NVXCoV2373, the Companys recombinant COVID-19 vaccine candidate adjuvanted with Matrix-M, was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. The data have been submitted for peer-review to a scientific journal and to an online preprint server at... More

Novavax (NVAX) Covid-19 Vaccine Induces Immune Response in First Human Study, Company Says - DJ

August 4, 2020 4:01 PM EDT

(Updated - August 4, 2020 4:02 PM EDT)

Novavax (NASDAQ: NVAX) Covid-19 Vaccine Induces Immune Response in First Human Study, Company Says - DJ

Data Supports Further Tests, Plans Large Study in Fall... More